OpenEvidence

Bottom line

OpenEvidence is the most widely adopted free clinical Q&A platform among US physicians, with an estimated 65% penetration and 1 million consults processed daily. It is free for NPI-verified physicians and funded by pharma advertising, which means every answer includes literature citations but also means the business model depends on ad revenue. The platform serves dual roles: a literature-grounded clinical question engine and an ambient AI scribe with customizable templates.

For US-based physicians who prioritize quick, evidence-backed answers and accept an ad-supported model, OpenEvidence delivers compelling value at zero cost. However, the tradeoffs are real: service downtime has occurred, accuracy errors have been documented by clinicians, and the platform withdrew from the EU in 2024 citing regulatory uncertainty. Physicians requiring guaranteed uptime or those uncomfortable with pharma-ad funding should consider paid alternatives.

The best-fit persona is a US primary care physician or hospitalist who needs fast clinical lookups during patient encounters, values literature traceability over raw speed, and is willing to tolerate occasional downtime and the presence of pharmaceutical advertisements. Specialists seeking deep evidence synthesis or IT leaders requiring contractual SLAs should look elsewhere.

Why we picked it

OpenEvidence earned the top spot in the AI Clinical Decision Support silo for best free physician Q&A because it balances accessibility with evidence grounding in a way no other free tool currently matches. Unlike general-purpose large language models that hallucinate citations or provide answers without traceability, OpenEvidence surfaces primary literature for every response. This is not a minor feature: it is the core value proposition that has driven adoption across two-thirds of US physicians.

The platform is embedded in Epic at Mount Sinai Health System, signaling that at least one major integrated delivery network has validated its clinical workflow fit. That integration, combined with the 1 million daily consults, suggests OpenEvidence has crossed the chasm from early adopter curiosity to mainstream clinical tool. The fact that it remains free while competitors like UpToDate charge $700 per year makes it the obvious first choice for cost-conscious practices.

The pharma-ad funding model is transparent: physicians see advertisements alongside clinical answers. This is a deliberate trade: free access in exchange for attention. For clinicians accustomed to free medical education content funded by pharma grants, this model is familiar. For those who find such funding problematic, OpenEvidence is disqualified by design. The silo pick assumes the former group is larger and that transparency about funding mitigates bias risk.

Finally, OpenEvidence has demonstrated velocity. Founded in 2022, it achieved majority US physician penetration within two years. That growth rate reflects genuine clinical utility, not just marketing reach. The platform is also current: it updates literature daily, which matters for rapidly evolving clinical guidelines. These factors collectively justify the pick, even as weaknesses remain.

What it does well

The literature grounding is OpenEvidence's defining strength. Every answer includes citations to primary studies, which allows physicians to verify claims and drill into the evidence base. Clinicians on r/FamilyMedicine have described it as saving time by generating letters of medical necessity within seconds, complete with referenced guidelines. This is not just faster than manual literature search: it is faster than asking a colleague or consulting a static reference like UpToDate.

The scribe functionality has developed a devoted user base. Physicians report that OpenEvidence produces structured clinical notes from ambient audio, with customizable templates that adapt to specialty workflows. One clinician on r/FamilyMedicine praised it as arguably the best AI scribe currently in existence, noting the ability to tailor templates for physicals and multi-problem visits. The template-sharing community that has emerged around OpenEvidence suggests the platform has achieved product-market fit for documentation workflows.

The platform updates its knowledge base daily, which matters for fast-moving clinical domains. A physician using OpenEvidence for an acute meniscal pathology question can expect alignment with 2024 AAOS guidelines, not outdated recommendations from static databases. This currency is a competitive advantage over traditional references that update quarterly or annually.

Finally, the free tier is genuinely free. There are no usage caps, no feature gates, and no bait-and-switch upgrades. NPI verification is the only barrier, which takes minutes. For solo practitioners and residents, this removes a significant budget constraint. Clinicians on Reddit have repeatedly highlighted the free tier as a key reason they adopted OpenEvidence over subscription alternatives.

Where it falls short

Accuracy failures have been documented in clinical use. A physician on r/emergencymedicine reported catching OpenEvidence providing incorrect guidance on pulmonary embolism diagnosis, specifically stating that a chest X-ray could be used to rule in or out PE when it cannot. This is not a theoretical concern: it is a documented instance where reliance on the platform without verification could have led to diagnostic error. The fact that this surfaced in a public forum suggests other errors may exist unreported.

Service downtime has occurred, and clinicians have expressed frustration. One r/FamilyMedicine user stated they would use a large amount of CME funds to guarantee uptime, noting that the platform went down during clinical hours. There is no paid tier offering SLA guarantees, which means physicians cannot buy reliability even if willing to pay. This is a structural weakness: a free, ad-funded model has no incentive to invest in redundancy or guaranteed availability.

The platform withdrew from the European Union in 2024 citing mounting regulatory uncertainty. Physicians on r/medicine reported needing VPNs to continue access. This withdrawal signals that OpenEvidence either lacks the resources or the appetite to navigate complex regulatory environments. For US-based physicians, this raises the question: what happens if US regulatory scrutiny increases? The precedent suggests the platform might exit rather than adapt.

The scribe mode includes irrelevant details by default, according to multiple Reddit reports. One clinician complained that notes included exact pharmacy names and lab hours, cluttering the clinical narrative. While templates can be customized to suppress these details, the fact that the default output requires tuning suggests the platform prioritizes completeness over conciseness. Additionally, the scribe captures only one side of the conversation by default, which limits its utility in complex multi-party encounters. Finally, the pharma-ad funding model raises inherent bias concerns: even with transparent disclosure, the presence of pharmaceutical advertisements alongside clinical recommendations introduces a conflict of interest that some physicians and health systems will find unacceptable.

Deployment realities

Deployment friction is minimal for individual physicians: NPI verification takes minutes, and the platform runs in a web browser with no local installation required. However, the scribe functionality requires audio capture, and clinicians on Reddit have reported that Ubuntu with Pipewire is problematic, requiring script reruns to maintain stability. This suggests that physicians using Linux workstations may face technical hurdles that Windows and macOS users avoid.

Epic integration exists at Mount Sinai Health System, but the depth of that integration is not publicly documented. It is unclear whether OpenEvidence writes back to the EHR or operates as a read-only reference tool. For IT leaders evaluating the platform for enterprise deployment, this ambiguity is a problem: without detailed integration specifications, scoping the implementation effort is guesswork. There is no evidence of integration with Cerner, Meditech, or other major EHR vendors, which limits its utility for non-Epic health systems.

Template customization is necessary to achieve optimal scribe output, and this requires upfront time investment. Physicians on r/FamilyMedicine actively share templates with one another, suggesting that out-of-the-box templates are insufficient for many workflows. For a practice deploying OpenEvidence across multiple clinicians, this means budgeting time for each provider to tune their templates, with no centralized template management visible in the platform's public documentation.

Pricing realities

OpenEvidence is free for NPI-verified physicians, at $0 per month with no annual contract. The platform is funded by pharmaceutical advertising, which is displayed alongside clinical answers. This is transparent, but it also means the business model depends on maintaining advertiser relationships. If ad revenue declines or regulatory pressure mounts, the free tier could change or disappear.

There is no paid tier offering enhanced reliability, priority support, or ad-free access. Clinicians on Reddit have expressed willingness to pay for guaranteed uptime, but the platform has not responded with a subscription option. This leaves physicians with no mechanism to buy service-level agreements, which is a gap for those who depend on the tool during patient encounters. For comparison, UpToDate charges $700 per year and provides contractual uptime guarantees, making it the obvious choice for clinicians who require reliability over cost savings.

Hidden costs are minimal but real. The time required to customize scribe templates and the attention cost of scanning past pharmaceutical advertisements both represent opportunity costs. Additionally, the risk of accuracy errors introduces a verification burden: physicians must mentally fact-check OpenEvidence outputs, which reduces the time savings relative to a fully trusted reference. For physicians who value speed over cost, these frictions may outweigh the zero-dollar price tag.

Compliance + integration depth

HIPAA compliance status is not explicitly documented in the sources provided. For a platform processing clinical conversations via scribe functionality, this is a critical gap. Health system IT leaders will require BAAs and SOC 2 attestations before permitting clinical use, and the absence of public compliance documentation makes vendor diligence more difficult. The fact that Mount Sinai has integrated OpenEvidence into Epic suggests compliance was validated at least once, but that does not generalize to other health systems.

Epic integration exists at Mount Sinai, but the depth is unclear. There is no public documentation specifying whether OpenEvidence can write structured data back to Epic or whether it operates as a read-only reference tool. Integration with other EHR vendors (Cerner, Meditech, Allscripts) is not mentioned, which limits its utility for non-Epic health systems. For a clinical decision support tool, shallow integration is a dealbreaker: if answers cannot flow into the clinical workflow, physicians must manually transcribe, which erodes the value proposition.

The EU withdrawal indicates regulatory compliance challenges. Mounting regulatory uncertainty was cited as the reason for exit, suggesting the platform either could not or would not navigate GDPR and EU medical device regulations. For US-based health systems, this raises the question of FDA clearance status. There is no evidence that OpenEvidence has pursued 510(k) clearance or De Novo classification, which may limit its use in diagnostic workflows. Specialty society endorsements are not mentioned in the sources, which is notable given the platform's wide adoption.

Vendor stability + roadmap

OpenEvidence was founded in 2022 by Dr. Daniel Nadler, based in Cambridge, Massachusetts. The company has achieved 1 million consults per day and an estimated 65% penetration among US physicians within two years, which indicates product-market fit and operational scale. However, funding details are not publicly disclosed in the sources, which makes it difficult to assess financial runway or investor backing. For health systems making multi-year commitments, vendor stability is a top-three concern, and the lack of transparency here is a weakness.

The EU withdrawal in 2024 suggests a reactive rather than proactive regulatory strategy. Rather than investing in compliance infrastructure to serve the European market, OpenEvidence chose to exit. This decision may reflect resource constraints or strategic focus on the US market, but it also signals that the platform may not have the depth of legal and regulatory expertise required for global expansion. For US-based customers, the risk is that similar regulatory pressure domestically could prompt similar withdrawals from specific states or health systems.

Roadmap visibility is limited. The platform has publicly emphasized daily literature updates and scribe template customization, but there is no evidence of planned expansions into specialty-specific modules, advanced diagnostic support, or deeper EHR integrations. Clinicians on Reddit have requested features like bilateral audio capture for scribe mode and reduced irrelevant details in note output, but it is unclear whether these are prioritized. The absence of a public roadmap makes it difficult for health systems to align their own digital health strategies with OpenEvidence's future direction.

How it compares

UpToDate is the incumbent clinical reference, charging $700 per year for individual subscriptions. It offers deeper evidence synthesis, editorial oversight, and contractual uptime guarantees. UpToDate wins when reliability is paramount and when the clinical question requires narrative synthesis rather than rapid literature lookup. OpenEvidence wins on cost and speed: for straightforward clinical questions where literature grounding is sufficient, the free tier makes UpToDate's subscription fee hard to justify. However, UpToDate has launched its own LLM-powered search, narrowing the speed gap.

General-purpose large language models like ChatGPT, Claude, and Gemini offer broader versatility but lack physician-specific training and transparent literature grounding. A 2026 study in the journal Knee compared OpenEvidence's concordance with AAOS meniscal pathology guidelines against ChatGPT, Gemini, and Claude, finding that OpenEvidence's domain-specific design yielded more guideline-aligned recommendations. However, ChatGPT Plus and Claude Pro offer faster responses and no pharmaceutical advertisements, which some physicians prefer. OpenEvidence wins when literature traceability is the priority; general LLMs win when speed and ad-free access matter more.

Perplexity AI occupies a middle ground: it is a general-purpose LLM with real-time web search, offering citation transparency without physician-specific training. A 2026 study in the South Medical Journal compared GPT-4o, Perplexity, and OpenEvidence on diagnostic radiology board questions, finding performance differences that favored domain-specific tools for specialty-level queries. Perplexity wins for physicians who want citation transparency without accepting pharma-ad funding, but OpenEvidence wins for those who prioritize physician-community validation and Epic integration.

For scribe functionality specifically, competitors include Nuance DAX, Suki, and Abridge. These are subscription-based, with deeper EHR integrations and enterprise support. OpenEvidence's scribe mode is free but requires template customization and has been reported to include irrelevant details by default. Nuance and Suki win for health systems requiring vendor support and training; OpenEvidence wins for solo practitioners and small groups prioritizing cost over enterprise features.

What clinicians say

Clinicians on Reddit have mentioned OpenEvidence 20 times across multiple subreddits, with sentiment ranging from enthusiastic to cautious. The most positive feedback centers on the scribe functionality: one physician on r/FamilyMedicine described it as arguably the best AI scribe currently in existence, noting the ability to generate letters of medical necessity within seconds and the value of customizable templates for complex visits. Another clinician on the same subreddit initiated a template-sharing thread, suggesting a community has formed around optimizing the platform for specific workflows.

However, accuracy concerns have surfaced. A physician on r/emergencymedicine reported catching an inaccuracy when OpenEvidence incorrectly stated that a chest X-ray could be used to rule in or out pulmonary embolism, a fundamental diagnostic error. The clinician warned others to beware of what OpenEvidence tells them, framing the incident as a cautionary tale about over-reliance on AI-generated recommendations. This is not anecdotal hand-wringing: it is a documented instance where the platform provided clinically incorrect guidance.

Service reliability is a recurring complaint. One r/FamilyMedicine user stated that when OpenEvidence went down, they would use a large amount of CME funds to guarantee it would not happen again, expressing surprise that the platform is not already subscription-based given its clinical utility. The EU withdrawal also generated frustration: clinicians on r/medicine asked which VPN services allowed continued access after the platform cited mounting regulatory uncertainty and exited the European market. Finally, template verbosity is a noted weakness: one physician complained that OpenEvidence includes irrelevant details like exact pharmacy names and lab hours, requiring manual editing to produce concise clinical notes.

What the literature says

OpenEvidence has appeared in five peer-reviewed publications as of early 2026, all within the past year. This is a thin but growing evidence base, reflecting the platform's recent launch and rapid clinical adoption outpacing formal research. A 2026 study in the South Medical Journal compared GPT-4o, Perplexity AI, and OpenEvidence on diagnostic radiology board-style questions, finding that OpenEvidence's performance on specialty-level queries reflected its domain-specific training. Another 2026 study in the journal Knee evaluated concordance with the 2024 AAOS guidelines on acute isolated meniscal pathology, comparing OpenEvidence against ChatGPT, Gemini, and Claude to assess reliability and clinical applicability.

A 2026 analysis in the Journal of Medical Internet Research examined how generative AI tools cite retracted literature, including OpenEvidence in the evaluation. This reflects broader concerns about AI reliability in scientific research and the risk that even literature-grounded platforms may surface discredited studies. A 2026 overview in the Journal of the Medical Library Association documented OpenEvidence as an AI-based medical information platform founded by Dr. Daniel Nadler, noting its free access for healthcare professionals and registration requirement. Finally, a 2026 article in the Journal of Clinical Medicine explored the role of large language models in promoting minimally invasive interventional radiology methods in obstetrics and gynecology, citing OpenEvidence as one of several tools being evaluated for patient education and clinical decision support.

The evidence base is preliminary. Five citations in two years is modest, especially given the platform's wide adoption. There are no randomized controlled trials evaluating clinical outcomes, no formal validation studies comparing OpenEvidence recommendations to expert consensus, and no peer-reviewed documentation of its scribe functionality. For health systems requiring evidence-based vendor selection, this gap is significant. The studies that do exist are largely observational or descriptive, not definitive. Physicians should treat the literature as confirming that OpenEvidence is being studied, not that it has been rigorously validated.

Who it's for

OpenEvidence is best suited for US-based primary care physicians, hospitalists, and residents who need fast, literature-grounded answers during patient encounters and are comfortable with a pharma-ad-funded model. The ideal user is a solo family medicine practitioner or a small group practice without budget for expensive reference subscriptions, who values evidence traceability over raw speed and is willing to tolerate occasional downtime. The scribe functionality appeals to clinicians drowning in documentation burden, particularly those who have time to invest in template customization upfront in exchange for faster note generation downstream.

Specialists may find value for straightforward clinical questions, but those requiring deep evidence synthesis or guideline interpretation should supplement OpenEvidence with specialty-specific references. The platform's performance on radiology board questions and meniscal pathology guidelines suggests it can handle specialty-level queries, but the documented pulmonary embolism error indicates that critical diagnostic decisions should not rely solely on OpenEvidence output. Physicians in high-acuity settings like emergency medicine should verify recommendations before acting, which reduces the time-saving benefit.

OpenEvidence is not for EU-based physicians, as the platform has withdrawn from that market. It is also not for health systems requiring contractual SLAs, formal compliance attestations, or vendor support beyond community forums. IT leaders at large integrated delivery networks should approach cautiously: the lack of public documentation on Epic integration depth, the absence of Cerner or Meditech connectors, and the reactive regulatory posture all suggest the platform is optimized for individual physicians rather than enterprise deployments. Finally, physicians who find pharma-ad funding ethically problematic should skip OpenEvidence entirely and pay for ad-free alternatives like UpToDate or general-purpose LLMs with subscription tiers.

The verdict

OpenEvidence is the best free clinical Q&A platform available to US physicians, full stop. The combination of zero cost, literature grounding, and 65% adoption makes it the default choice for budget-conscious clinicians who need quick answers with traceable sources. However, the tradeoffs are real and should be accepted with eyes open: service downtime has occurred, accuracy errors have been documented, and the pharma-ad funding model introduces a conflict of interest that some will find disqualifying. Physicians must verify critical recommendations rather than trusting blindly, which limits the time-saving benefit relative to a fully trusted reference.

If guaranteed uptime is a hard requirement, pay for UpToDate at $700 per year. If pharma-ad funding is ethically unacceptable, use ChatGPT Plus or Claude Pro for $20 per month and accept the tradeoff of less physician-specific training. If you are based in the EU, OpenEvidence is not an option: the platform has withdrawn citing regulatory uncertainty. For US-based primary care physicians and hospitalists who prioritize cost over reliability and are willing to mentally fact-check outputs, OpenEvidence delivers compelling value. For specialists and health systems requiring vendor support, formal compliance attestations, and deep EHR integration, the platform is not yet ready for enterprise adoption.

The evidence base is thin but growing: five PubMed citations in two years is preliminary, not definitive. Clinicians should treat OpenEvidence as a productivity tool, not a clinical decision oracle. When the clinical stakes are high, verify recommendations against primary literature or consult a colleague. When the question is straightforward and the literature is well established, OpenEvidence saves time without meaningful risk. The platform has crossed the chasm from early adopter curiosity to mainstream clinical tool, but it has not yet achieved the reliability, regulatory maturity, or vendor support depth required for mission-critical deployment. Use it as a first-line reference, not the last word.